Compositions and methods for the treatment of irritable bowel syndrome

Abstract

The disclosures herein provide compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, formula XII, formula XIII, formula XIV and formula XV or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, suppository, transdermal, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of irritable bowel syndrome (IBS), inflammatory bowel diseases or its associated complications.

What is claimed is: 
     
         1 . (canceled) 
     
     
         2 . A compound of Formula II: 
       
         
           
           
               
               
           
         
         or pharmaceutically acceptable salts, hydrates, solvates, enantiomers, or stereoisomers thereof, wherein 
         R 1 , R 2  each independently represents NULL, 
       
       
         
           
           
               
               
           
         
         R 2 , R 4 , R 6  each independently represent D, OD, 
       
       
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         
           
           
               
               
           
         
         n is independently 1, 2, 3, 4 or 5; 
         a is independently 2, 3 or 7; 
         each b is independently 3, 5 or 6; 
         e is independently 1, 2 or 6; 
         c and d are each independently H, D, —OH, —OD, C 1 -C 6 -alkyl, —NH 2  or —COCH 3 ; 
         within the proviso that there is 
       
       
         
           
           
               
               
           
         
         Each i independently represents 
       
       
         
           
           
               
               
           
         
       
     
     
         3 . (canceled) 
     
     
         4 . A pharmaceutical composition comprising a compound of  claim 2  and a pharmaceutically acceptable carrier. 
     
     
         5 . (canceled) 
     
     
         6 . The pharmaceutical composition of  claim 4 , wherein said pharmaceutical composition is formulated to treat a subject by administering said pharmaceutical composition to the subject by oral administration, delayed release or sustained release, transmucosal, administration, syrup, topical administration, parenteral administration, injection, subdermal, administration, oral solution, rectal administration, buccal administration or transdermal administration. 
     
     
         7 . (canceled) 
     
     
         8 . The pharmaceutical composition of  claim 6 , wherein said composition is formulated for the treatment of inflammatory bowel disease, crohn's disease, irritable bowel syndrome, coeliac disease, fructose malabsorption, mild infections, parasitic infections like giardiasis, bile acid malabsorption, functional chronic constipation, small intestinal bacterial overgrowth, and chronic functional abdominal pain. 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . A compound of  claim 2 , wherein the compound is: 
       
         
           
           
               
               
           
         
       
     
     
         12 . A pharmaceutical composition comprising a compound of  claim 11  and a pharmaceutically acceptable carrier. 
     
     
         13 . The pharmaceutical composition of  claim 12 , wherein said pharmaceutical composition is formulated to treat a subject by administering said pharmaceutical composition to the subject by oral administration, delayed release or sustained release, transmucosal administration, syrup, topical administration, parenteral administration, injection, subdermal administration, oral solution, rectal administration, buccal administration or transdermal administration. 
     
     
         14 . The pharmaceutical composition of  claim 13 , wherein said composition is formulated for the treatment of inflammatory bowel disease, crohn's disease, irritable bowel syndrome, coeliac disease, fructose malabsorption, mild infections, parasitic infections like giardiasis, bile acid malabsorption, functional chronic constipation, small intestinal bacterial overgrowth, and chronic functional abdominal pain. 
     
     
         15 . A method of treating at least one of an intestinal, an immune mediated disease and an inflammatory disease comprising: administering the compound of  claim 11  to patient suffering from at least one of an intestinal, an immune mediated disease and an inflammatory disease. 
     
     
         16 . A method of treating at least one of an intestinal disease, an immune mediated disease and an inflammatory disease by administering a compound to patient suffering from at least one of an intestinal disease, an immune mediated disease and an inflammatory disease, wherein the compound is independently selected from the group consisting of: